Safety and efficacy of stem cell therapy for inflammatory bowel disease

doi:10.3877/cma.j.issn.2095-2015.2018.02.006

Abstract

Abstract:

Inflammatory bowel disease(IBD)is a group of diseases on the basis of complex etiology and pathophysiology changes involving the changes of intestinal microflora, abnormal immune response, damage of important barrier offered by intestinal epithelial cells and vascular system, and is a kind of incurable disease.There are obvious deficiencies in traditional treatment, such as drug treatment and surgical excision.In recent years, stem cells have opened up a new method for the treatment of IBD because of their biological characteristics.This review summarizes the shortcomings of traditional treatment for IBD, and analyzes the safety and efficacy that stem cells transplantation treats IBD, especially mesenchymal stem cells.

Key words: Inflammatory bowel disease, Mesenchymal stem cells, Safety, Efficacy

Xiu Wang, Yiguo Wang. Safety and efficacy of stem cell therapy for inflammatory bowel disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(02): 71-75.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2018.02.006

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2018/V08/I02/71

References 40

1	Nagaishi K, Arimura Y, Fujimiya M. Stem cell therapy for inflammatory bowel disease[J]. J Gastroenterol, 2015, 50(3): 280-286.
2	Flores AI, Gómez-Gómez GJ, Masedo-Gonzálezá, e al.Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy？[J]. World J Stem Cells, 2015, 7(2): 343-351.
3	Duran NE, Hommes DW.Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls[J]. Ther Adv Gastroenterol, 2016, 9(4)533-547.
4	Dave M, Papadakis KA, Faubion WA Jr.Immunology of inflammatory bowel disease and molecular targets for biologics[J]. Gastroenterol Clin North Am, 2014, 43(3): 405-424.
5	Hommes D, Colombel JF, Emery P, et al.Changing Crohn′s disease management: Need for new goals and indices to prevent disability and improve quality of life [J]. Am J Gastroenterol, 2010, 105(2): 289-297.
6	Billioud V, Ford AC, Tedesco ED, et al.Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta analysis[J]. Crohns Colitis, 2013, 7(11): 853-867.
7	Dalal J, Gandy K, Domen J. Role of mesenchymal stem cell therapy in Crohn′s disease[J]. Pediatr Res, 2012, 71(4 Pt 2): 445-451.
8	Panaccione R, Ghosh S, Middleton S, et al.Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology, 2014, 146(2): 392-400.e3.
9	Thomas A, Lodhia N. Advanced therapy for inflammatory bowel disease: a guide for the primary care physician[J]. J Am Board Fam Med, 2014, 27(3): 411-420.
10	Peyrin-Biroulet L, Loftus EVJ, Colombel JF, Sandborn WJ.The natural history of adult Crohn′s disease in population-based cohorts[J]. Am J Gastroenterol, 2010, 105(2): 289-297.
11	D′Haens G, Baert F, van Assche G et al.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn′s disease: An open randomised trial[J]. Lancet, 2008, 371(9613): 660-667.
12	Burisch J, Jess T, Martinato M, Lakatos PL.ECCO-EpiCom: The burden of inflammatory bowel disease in Europe[J]. J Crohns Colitis, 2013, 7(4): 322-337.
13	Bernstein CN, Loftus EV Jr, Ng SC, et al.Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease(IOIBD): Hospitalisations and surgery in Crohn′s disease[J]. Gut, 2012, 61(4): 622-629.
14	Chatu S, Saxena S, Subramanian V, et al.The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn′s disease: national UK population-based study 1989-2010[J]. Am J Gastroenterol, 2014, 109(3): 409-416.
15	Zand A, Van Deen W, Inserra E, et al.Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact[J]. Inflamm Bowel Dis, 2015, 21(7): 1623-1630.
16	Armstrong L, Lako M, Buckley N, et al.Editorial: our top 10 developments in stem cell biology over the last 30 years[J]. Stem Cells, 2012, 30(1): 2-9.
17	Shroff G. Human Embryonic Stem Cell Therapy in Crohn′s Disease: A Case Report[J]. Am J Case Rep, 2016, 17(2): 124-128.
18	Okamoto R, Watanabe M. Investigating cell therapy for inflammatory bowel disease[J]. Expert Opin Biol Ther, 2016, 16(8): 1015-1023.
19	Hawkey CJ.Stem cells as treatment in inflammatory bowel disease[J]. Dig Dis, 2012；30(suppl 3): 134-139.
20	Shaker A, Rubin DC.Stem cells: One step closer to gut repair[J]. Nature, 2012, 485(7397): 181-182.
21	Tyndall A, Gratwohl A. Adult stem cell transplantation in autoimmune disease[J]. Curr Opin Hematol, 2009, 16(4): 285-291.
22	Caplan AI, Dennis JE.Mesenchymal Stem Cells as Trophic Mediators[J]. J Cell Biochem, 2006, 98(5): 1076-1084.
23	Caplan AI.Why are MSCs therapeutic? New data: new insight[J]. J Pathol, 2009, 217(2): 318-324.
24	Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system[J]. Nat Rev Immunol, 2012, 12(5): 383-396.
25	Raffaghello L, Bianchi G, Bertolotto M, et al.Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche[J]. Stem Cells, 2008, 26(1): 151-162.
26	Benvenuto F, Ferrari S, Gerdoni E, et al.Human mesenchymal stem cells promote survival of T cells in a quiescent state[J]. Stem Cells, 2007, 25(7): 1753-1760.
27	汪维伟，徐艳华，姜蓉，等．骨髓间充质干细胞移植治疗大鼠溃疡性结肠炎[J]．中国组织工程研究，2012，16(32): 6030-6036.
28	Manieri NA, Mack MR, Himmelrich MD, et al.Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis[J]. J Clin Invest, 2015, 125(9): 3606-3618.
29	Ciccocioppo R, Bernardo ME, Sgarella A, et al.Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn′s disease[J]. Gut, 2011, 60(6): 788-798.
30	Grégoire C, Lechanteur C, Briquet A, et al.Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2017, 45(2): 205-221.
31	杨波，赵振林，樊强．自体骨髓间充质干细胞治疗溃疡性结肠炎疗效分析[J]．临床医药实践，2015，24(7): 493-497.
32	Duijvestein M, Vos ACW, Roelofs H, et al.Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn′s disease: results of a phase I study[J]. Gut, 2010, 59(12): 1662-1669.
33	Forbes GM, Sturm MJ, Leong RW, et al.A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn′s disease refractory to biologic therapy[J]. Clin Gastroenterol Hepatol, 2014 12(1): 64-71.
34	Algeri M, Conforti A, Pitisci A, et al.Mesenchymal stromal cells and chronic inflammatory bowel disease[J]. Immunol Lett, 2015, 168(2): 191-200.
35	Lalu MM, McIntyre L, Pugliese C, et al.Safety of cell therapy with mesenchymal stromal cells(SafeCell): a systematic review and meta-analysis of clinical trials[J]. PLoS One, 2012, 7(10): e47559.
36	Guadalajara H, Herreros D, De-La-Quintana P, et al.Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas[J]. Int J Colorectal Dis, 2012, 27(5): 595-600.
37	Hawkey CJ, Snowden JA, Lobo A, et al.Stem cell transplantation for inflammatory bowel disease: practical and ethical issues[J]. Gut, 2000, 46(6): 869-872.
38	Almeida-Porada G, Soland M, Boura J, et al.Regenerative medicine: prospects for the treatment of inflammatory bowel disease[J]. Regen Med, 2013, 8(5): 631-644.
39	Duricova D. What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease？[J]. Dig Dis, 2017 35(1/2): 69-73.
40	Munir H, McGettrick HM.Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards[J]. Stem Cells Dev, 2015, 24(18): 2091-100.

[1]	Jinglong He, Hongxi Shang, Min Hao, Wei Xie, Minghong Gao, Wei Sun, Anqing Liu. Clinical effect of multiple joints replacements in patients with severe rheumatoid arthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 860-864.
[2]	Yangwenxiang Wei, Haoran Huang, Yuhao Liu, Zhenqiu Chen, Haibin Wang, Chi Zhou. Outlooks and challenges in cell therapy of osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 694-700.
[3]	Hua Zhang, Yu Sun, Shijian Xiang, Yingmei Li, Xiaoqun Wang. Research on chemosensitivity evaluation using circulating tumor cells in advanced gastrointestinal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 422-425.
[4]	Haiqin Tang, Xiuzhi Guo, Xiaosu Zhu, Shidi Zhao. Clinical safety study of "tunnel method" laparoscopic anatomic left hemihepatectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 674-677.
[5]	Qingqing Zhu, Zhenqi Wei. Application value of self-efficacy management during perioperative period in patients with inguinal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 773-777.
[6]	Jun Liu, Ji Zhu, Jun Yin. Anesthesia effect and safety of dexmedetomidine in inguinal hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(05): 570-573.
[7]	Fengjie Wang, Liguang Wang, Shan Liao, Ying Liu, Rongdang Fu, Huanwei Chen. Safety and efficacy of laparoscopic right hemihepatectomy for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 517-522.
[8]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[9]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[10]	Lijiao Jiang, Feng Zhang, Yuping Zhou. Clinical efficacy observation of treating elderly patients with acute non-variceal upper gastrointestinal hemorrhage using the MDT model [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 520-524.
[11]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[12]	Jingxu Zhang, Defang Li, Shangke You, Yutian Zhang. Clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 289-293.
[13]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[14]	Juan Zhang, Jiayan Zhuang, Yingmei Yang, Shengrong Jiang, Yan Su, Zhenxing Liu. Comparison of diagnostic efficacy of contrast-enhanced ultrasound and upper abdominal enhanced magnetic resonance in patients with hepatic hemangioma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 220-223.
[15]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.

Please choose a citation manager

Content to export